Sort
30,917 grants matching “tumor microenvironment”
Improving CAR-T efficacy against solid tumors by expanding lymph node reservoirs of âstem-likeâ CAR-T cells
$579,054Shivani Srivastava · Fred Hutchinson Cancer Center · R37 · FY2023 · CA
Influences of the Microenvironment on Cancer Stem Cells
$579,004Hong Wu · University Of California Los Angeles · U01 · FY2014 · CA
Role of p62 in metabolic reprograming of the tumor stroma in prostate cancer
$578,994Maria Teresa Diaz Meco Conde · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2017 · CA
In vivo efficacy, safety and PK/PD analysis of SYN101, a first in class, immune cell targeted TGFb therapy for cancer patients
$578,977Dori A Thomas-Karyat · Synthis Therapeutics, Inc. · R44 · FY2024 · CA
Polyamines and Hypusine in Type 1 Diabetes Pathogenesis
$578,915Raghavendra G Mirmira · University Of Chicago · R01 · FY2025 · DK
Delineating Functional Immunity via Image-Guided PET
$578,749Nerissa Therese Viola · Wayne State University · R37 · FY2023 · CA
Pathogenesis of the cART unresponsive Kaposiâs sarcoma tumor niche
$578,668Michael Shannon McGrath · University Of California, San Francisco · R01 · FY2019 · CA
Project 2: Local immunotherapy corrects chemokine patterns in ovarian cancer
$578,652Robert Page Edwards · Roswell Park Cancer Institute Corp · P01 · FY2020 · CA
Targeted immuno-nanoparticles for directing antitumor immune response against breast cancer metastasis
$578,640Efstathios Karathanasis · Case Western Reserve University · R01 · FY2022 · CA
Single Cell Methods for Bioeffector Discovery and Analysis
$578,443Brian O Bachmann · Vanderbilt University · R01 · FY2021 · CA
Towards Translation of MU-CN29: New Therapeutic Nanoparticle for Drug-Resistant NSCLC
$578,421Raghuraman Kannan · University Of Missouri-Columbia · R01 · FY2023 · CA
(PQ6) Mesenchymal stem cell based and immunocompetent mouse models of HIV/AIDS KSHV-driven sarcomagenesis
$578,253Enrique A Mesri · University Of Miami School Of Medicine · R01 · FY2021 · CA
Dissecting Tumor-Immune Interactions in HIV-HPV Co-Infection-Associated Oropharyngeal Cancer using Single Cell Sequencing and Novel Mouse Models
$578,249Shanye Yin · Albert Einstein College Of Medicine · R01 · FY2025 · CA
Dissecting Tumor-Immune Interactions in HIV-HPV Co-Infection-Associated Oropharyngeal Cancer using Single Cell Sequencing and Novel Mouse Models
$578,249Shanye Yin · Albert Einstein College Of Medicine · R01 · FY2024 · CA
Elucidating the Immune Suppressive Mechanism of SIGLEC-15 in the Tumor Microenvironment
$578,201Jun Wang · New York University School Of Medicine · R01 · FY2025 · CA
Project 1:The Carolina Breast Cancer Study
$578,056Melissa A. Troester · Univ Of North Carolina Chapel Hill · P50 · FY2020 · CA
Targeted immuno-nanoparticles for directing antitumor immune response against breast cancer metastasis
$578,041Efstathios Karathanasis · Case Western Reserve University · R01 · FY2023 · CA
Development of irreversible electroporation-based rational combinations to potentiate the activity of cancer immunotherapy against pancreatic ductal adenocarcinoma
$577,925Chun Li · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Racially-associated MRI analysis and modeling for predicting aggressive prostate cancer
$577,780Kyung Hyun Sung · University Of California Los Angeles · R01 · FY2023 · CA
Computational imaging approaches to personalized gastric cancer treatment
$577,660Ruijiang Li · Stanford University · R01 · FY2023 · CA
Targeting SEC61 complex to overcome resistance to immunotherapy in GBM
$577,634Irina V Balyasnikova · Northwestern University At Chicago · R01 · FY2025 · CA
Reverse transcriptase inhibitor effects on the mobilome of colon cancer
$577,473David Tsai Ting · Massachusetts General Hospital · R01 · FY2021 · CA
Reverse transcriptase inhibitor effects on the mobilome of colon cancer
$577,473David Tsai Ting · Massachusetts General Hospital · R01 · FY2020 · CA
Verteporfin as a YAP/TAZ inhibitor for treatment of glioblastoma
$577,469Renee D Read · Emory University · R01 · FY2023 · NS
Uncovering treatment targets for peripheral nerve sheath tumor progression in NF1
$577,428David Andrew Largaespada · University Of Minnesota · R01 · FY2022 · NS